NZ613915B2 - Combination of glycopyrrolate, fluticasone and indacaterol - Google Patents
Combination of glycopyrrolate, fluticasone and indacaterol Download PDFInfo
- Publication number
- NZ613915B2 NZ613915B2 NZ613915A NZ61391512A NZ613915B2 NZ 613915 B2 NZ613915 B2 NZ 613915B2 NZ 613915 A NZ613915 A NZ 613915A NZ 61391512 A NZ61391512 A NZ 61391512A NZ 613915 B2 NZ613915 B2 NZ 613915B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- fluticasone
- glycopyrronium
- pharmaceutical composition
- glycopyrrolate
- indacaterol
- Prior art date
Links
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 title claims abstract description 149
- 229960002462 glycopyrronium bromide Drugs 0.000 title claims abstract description 143
- 229940015042 Glycopyrrolate Drugs 0.000 title claims abstract description 43
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 title claims abstract description 35
- 229960002714 fluticasone Drugs 0.000 title claims abstract description 35
- QZZUEBNBZAPZLX-QFIPXVFZSA-N Indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 title claims abstract description 30
- 229960004078 indacaterol Drugs 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 163
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 64
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000002757 inflammatory Effects 0.000 claims abstract description 16
- 230000000414 obstructive Effects 0.000 claims abstract description 16
- 230000000241 respiratory Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 83
- 238000009472 formulation Methods 0.000 claims description 65
- XTULMSXFIHGYFS-VLSRWLAYSA-N Fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims description 58
- 229960001469 fluticasone furoate Drugs 0.000 claims description 54
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 229940071648 Metered Dose Inhaler Drugs 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 208000006673 Asthma Diseases 0.000 claims description 10
- IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 claims description 8
- 229960004735 indacaterol maleate Drugs 0.000 claims description 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 7
- 229940112141 Dry Powder Inhaler Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229940100662 Nasal Drops Drugs 0.000 claims description 4
- 239000007923 nasal drop Substances 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- 230000002354 daily Effects 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 230000000069 prophylaxis Effects 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 229940097496 Nasal Spray Drugs 0.000 claims description 2
- 229960004286 olodaterol Drugs 0.000 abstract description 54
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 abstract description 54
- 239000003246 corticosteroid Substances 0.000 abstract description 35
- DAFYYTQWSAWIGS-DEOSSOPVSA-N Vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 abstract description 29
- 229960004026 vilanterol Drugs 0.000 abstract description 29
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 abstract description 25
- 229960002848 formoterol Drugs 0.000 abstract description 25
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1H-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 abstract description 16
- 229950010713 Carmoterol Drugs 0.000 abstract description 16
- 229960001664 Mometasone Drugs 0.000 abstract description 14
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract description 14
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 abstract description 9
- 229960001334 Corticosteroids Drugs 0.000 abstract description 9
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 abstract description 9
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 172
- 229940005644 glycopyrronium Drugs 0.000 description 94
- 239000000725 suspension Substances 0.000 description 85
- 238000002156 mixing Methods 0.000 description 81
- 235000019441 ethanol Nutrition 0.000 description 63
- 229910052782 aluminium Inorganic materials 0.000 description 54
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 54
- 229960001375 Lactose Drugs 0.000 description 52
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 52
- 239000008101 lactose Substances 0.000 description 52
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 45
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 44
- 239000000556 agonist Substances 0.000 description 35
- 239000004615 ingredient Substances 0.000 description 31
- 239000005642 Oleic acid Substances 0.000 description 22
- 239000002775 capsule Substances 0.000 description 22
- -1 phenanthrenyl ester Chemical class 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 230000003182 bronchodilatating Effects 0.000 description 16
- 239000000443 aerosol Substances 0.000 description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 15
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 15
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 14
- 229940067606 Lecithin Drugs 0.000 description 14
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 239000000787 lecithin Substances 0.000 description 14
- 235000010445 lecithin Nutrition 0.000 description 14
- 229960002744 mometasone furoate Drugs 0.000 description 14
- 241000048284 Potato virus P Species 0.000 description 13
- 239000007921 spray Substances 0.000 description 13
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-Furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 230000001078 anti-cholinergic Effects 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 101700064702 LABA Proteins 0.000 description 11
- 239000000168 bronchodilator agent Substances 0.000 description 11
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000812 cholinergic antagonist Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 229960001021 Lactose Monohydrate Drugs 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 229960002282 vilanterol trifenatate Drugs 0.000 description 8
- KLOLZALDXGTNQE-JIDHJSLPSA-N vilanterol trifenate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1.C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 KLOLZALDXGTNQE-JIDHJSLPSA-N 0.000 description 8
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 7
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 7
- 239000003380 propellant Substances 0.000 description 7
- 229960004017 salmeterol Drugs 0.000 description 7
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- 102100008225 YME1L1 Human genes 0.000 description 6
- 101710025802 YME1L1 Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 6
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 5
- 206010038683 Respiratory disease Diseases 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 229960000289 fluticasone propionate Drugs 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 4
- 229960004436 Budesonide Drugs 0.000 description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 4
- 229960001031 Glucose Drugs 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000002035 prolonged Effects 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 229960004373 Acetylcholine Drugs 0.000 description 3
- 206010006334 Breathing abnormality Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 3
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000008139 complexing agent Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 229940050411 fumarate Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 238000002663 nebulization Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 229940110309 tiotropium Drugs 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BPXZSHHCUKRDHD-HTLUESNNSA-N (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPXZSHHCUKRDHD-HTLUESNNSA-N 0.000 description 2
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (E)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 description 2
- 229940090167 Advair Drugs 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 229940092705 Beclomethasone Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- RWRIWBAIICGTTQ-UHFFFAOYSA-N Difluoromethane Chemical compound FCF RWRIWBAIICGTTQ-UHFFFAOYSA-N 0.000 description 2
- 206010013642 Drooling Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229940093915 Gynecological Organic acids Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 2
- 102100020537 NIBAN2 Human genes 0.000 description 2
- 101710003558 NIBAN2 Proteins 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960004793 Sucrose Drugs 0.000 description 2
- YYAZJTUGSQOFHG-RZFXJYHSSA-N [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino] Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-RZFXJYHSSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000494 adverse effect Toxicity 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 230000002009 allergen Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001668 ameliorated Effects 0.000 description 2
- 230000001022 anti-muscarinic Effects 0.000 description 2
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 230000003454 betamimetic Effects 0.000 description 2
- 150000003842 bromide salts Chemical class 0.000 description 2
- 230000003435 bronchoconstrictive Effects 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 229940000425 combination drugs Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940021593 formoterol and fluticasone Drugs 0.000 description 2
- 229960000193 formoterol fumarate Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000000420 mucociliary Effects 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002496 poly(ether sulfone) Polymers 0.000 description 2
- 229920003208 poly(ethylene sulfide) Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- ZDUPYZMAPCZGJO-NSCGSSGESA-N (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 ZDUPYZMAPCZGJO-NSCGSSGESA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-M 2,2,2-triphenylacetate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)[O-])C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-M 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OCISOSJGBCQHHN-UHFFFAOYSA-M 4-carboxynaphthalen-2-olate Chemical compound C1=CC=CC2=CC(O)=CC(C([O-])=O)=C21 OCISOSJGBCQHHN-UHFFFAOYSA-M 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4H-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- WHJKCPTVEYZNOG-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxy-2-[4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane-3,4-diol Chemical compound COCC1OC(OC)C(OC)C(OC)C1OC1C(O)C(O)C(OC)C(CO)O1 WHJKCPTVEYZNOG-UHFFFAOYSA-N 0.000 description 1
- 229960000583 Acetic Acid Drugs 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 206010010264 Condition aggravated Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940096516 Dextrates Drugs 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920002068 Fluorinated ethylene propylene Polymers 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N Fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000004969 Inflammatory Cells Anatomy 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 Interleukin-8 Drugs 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229960001888 Ipratropium Drugs 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N Isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N Isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- CRSOQBOWXPBRES-UHFFFAOYSA-N Neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 206010061877 Obstructive airways disease Diseases 0.000 description 1
- 206010073310 Occupational exposure Diseases 0.000 description 1
- 229960002969 Oleic Acid Drugs 0.000 description 1
- 229960001733 Olodaterol hydrochloride Drugs 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 229920000006 Perfluoroalkoxy alkane Polymers 0.000 description 1
- 239000004813 Perfluoroalkoxy alkane Substances 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 229960003975 Potassium Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K Potassium citrate Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 210000001533 Respiratory Mucosa Anatomy 0.000 description 1
- 210000003019 Respiratory Muscles Anatomy 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229940035073 Symbicort Drugs 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N Tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 210000001186 Vagus Nerve Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L Zinc chloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003266 anti-allergic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 230000001713 cholinergic Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001120 cytoprotect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- DYDNPESBYVVLBO-UHFFFAOYSA-N formanilide Chemical compound O=CNC1=CC=CC=C1 DYDNPESBYVVLBO-UHFFFAOYSA-N 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- SYCWERNQGSKYAG-QVRIGTRMSA-N hydron;8-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one;chloride Chemical compound Cl.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 SYCWERNQGSKYAG-QVRIGTRMSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- JUVSRACZYLMJQD-UHFFFAOYSA-N methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-phenylmethoxypyridine-2-carboxylate Chemical compound O=C1C=CN(CC(O)CO)C(C(=O)OC)=C1OCC1=CC=CC=C1 JUVSRACZYLMJQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003551 muscarinic Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001473 noxious Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- KCEHVJZZIGJAAW-FERBBOLQSA-N olodaterol hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 KCEHVJZZIGJAAW-FERBBOLQSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 231100000812 repeated exposure Toxicity 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 239000011791 tripotassium citrate Substances 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Provided are pharmaceutical compositions comprising glycopyrrolate, a beta2-adrenergic agonist, and optionally a corticosteroid. Exemplified beta2-adrenergic agonists include indacaterol, formoterol, vilanterol, carmoterol and olodaterol. Exemplified corticosteroids include fluticasone and mometasone. The compositions can be used in the treatment of respiratory, inflammatory or obstructive airway diseases. e. The compositions can be used in the treatment of respiratory, inflammatory or obstructive airway diseases.
Description
Combination of glycopyrrolate, fluticasone and indacaterol
Field of Invention
The present invention relates to pharmaceutical compositions for inhalation which
se one or more bronchodilators and optionally an inhaled corticosteroid. There is
also provided a process for preparing such compositions and the use thereof in the
treatment and/or prevention of respiratory, inflammatory or obstructive airway disease,
particularly chronic obstructive pulmonary disease.
Background of ion
Chronic obstructive pulmonary disease (COPD) is a severe respiratory condition that is
increasing its prevalence worldwide. In India, the estimated prevalence is about 12.36
million. It is currently the fourth leading cause of death in the UK & US, and predicted to
rank third in the global impact of disease by the year 2020.
COPD is a preventable and treatable disease state characterized by air flow tion that
is not fully reversible. The airflow obstruction is usually progressive and associated with
an abnormal inflammatory response of the lungs to noxious particles or gases, primarily
caused by cigarette g. Although COPD affects the lungs it also produces
cant systemic consequences. COPD is associated with mucus hyper secretion,
emphysema, bronchiolitis.
The major goals of COPD therapy include smoking cessation, relief of ms,
improvement in physiological functions and limiting complications, such as abnormal gas
exchange and exacerbation of disease. However, an integrated approach to the treatment
of COPD, involves a ation of healthcare maintenance such as smoking cessation,
avoidance of , outdoor pollutants and allergens, and avoidance of occupational
exposure to allergens, use of drugs and mental therapies in a ise fashion as
the e progresses.
Currently, therapy for the treatment or prevention of COPD and asthma includes the use
of one or more long acting bronchodilators and an inhaled osteroid (ICS).
Inhaled bronchodilators are the foundation in the therapy of COPD e of their
ty to alleviate symptoms, decrease exacerbations of disease and improve quality of
life. These drugs also improve airflow limitation and hyperinflation, thereby decreasing
the work of breathing and improving exercise tolerance. In addition, bronchodilators
may reduce respiratory muscle fatigue and improve mucociliary clearance.
More specifically, the choice of bronchodilators includes betag-agonists and
anticholinergics. Further, betaz-agonists can be short acting for immediate relief, or long
acting for long term prevention of asthma symptoms.
Long acting agonists (LABAs) improve lung function, reduce symptoms and
protect against exercise-induced dyspnea in patients with asthma and COPD. LABAs
induce bronchodilation by causing ged tion of airway smooth muscle. In
addition to prolonged bronchodilation, LABAs exert other effects such
as inhibition of
airway smooth-muscle cell proliferation and inflammatory mediator release, as well as
non smooth-muscle effects, such as stimulation of mucociliary transport, cytoprotection
of the respiratory mucosa and attenuation of neutrophil recruitment and activation.
Also, use of a LABA reduces the ncy of drug administration. Commercially
available LABAs include salmeterol and formoterol.
olinergic agents also act as bronchodilators and are potential alternatives to beta
agonists, particularly LABAs. r, anticholinergics can also be administered along
with LABAs for the management of asthma. Anticholinergics act by competing with
acetylcholine for the or sites at vagus nerve or nerve-muscle junctions. This
prevents the transmission of reflexes that are induced by asthma stimuli.
Use of anticholinergics provides an advantage in elderly patients as the responsiveness of
beta2~agonists declines with old age. Further it would be advantageous to use
anticholinergics in patients who are intolerant to the use of betaz-agonists.
Even though it is know that betaz—agonists provide a symptomatic relief in
bronchoconstriction, another ent of COPD, which is inflammation, requires a
separate treatment such as with steroids. Most of the inhaled corticosteroids need to be
administered in multiple dosage regimens.
Corticosteroids exhibit inhibitory effects on inflammatory cells and inflammatory
ors involved in the pathogenesis of respiratory disorders such as COPD.
ent with a corticosteroid/glueocorticoid is considered one of the most potent and
effective therapies tly available for COPD.
However, the use of corticosteroids has been limited due to potential side effects
associated with their use, including suppression of the Hypothalamic-Pituitary-Adrenal
(HPA) axis, adverse effects on bone growth in children and on bone density in the
elderly, ocular complications (cataract ion and glaucoma) and skin atrophy.
Commercially available corticosteroids include beclomethasone, budesonide, fluticasone,
mometasone, ciclesonide and triamcinolone.
tly, there are l commercially available pharmaceutical compositions for
inhalation comprising combinations of LABA and inhaled corticosteroid (ICS).
es of such ations for the treatment of asthma and chronic obstructive
pulmonary e (COPD) are salmeterol/fluticasone propionate (Advair® diskus®,
Advair® HFA), and erol fumarate dehydrate/budesonide (Symbicort®).
Thus combination therapy of a bronchodilator with an ICS improves pulmonary
efficiency, reduces inflammatory response and provides symptomatic relief as compared
to higher doses of ICS alone in patients affected by respiratory disorders such as COPD.
W0 2012/1 10770 PCT/G32012/000171
The selection of a specific bronchodilator and ICS plays a very important role in
ation of fixed dose combination therapies.
Further, combination therapy reduces the cost and also provides control of reSpiratory
disorders. Reducing the dose frequency to the minimum is a main step in simplifying
COPD management for improving patient adherence to the y.
USZOO9088408 discloses pharmaceutical compositions of anticholinergics,
corticosteroids and betamimetics and their use in the ent of atory diseases.
The es of this application are inhalable powders or suspension aerosol
compositions which contain tiotropium or opium bromide.
USZOOSO42174 discloses a combination of doses of a betaz-agonist, an anticholinergic
agent and an anti-inflammatory steroid.
W02006105401 discloses anticholinergic in combination with a corticosteroid, and a
long acting beta agonist, for simultaneous or tial administration in the prevention
or treatment of a respiratory, atory or obstructive airway disease.
U82008279948 discloses a medicament sing a betaz-agonist, a glycopyrronium
salt and mometasone furoate. The examples of this application contain the betaz-agonist
indacaterol maleate.
U82008286363 discloses a medicament comprising a agonist (such as indacaterol
maleate), a glycopyrronium salt and a corticosteroid. The examples of this application
contain the corticosteroid 3-methyl—thiophene-2~carboxylic acid
(6S,9R, 1 OS, 1 13,13 S, 16R, l7R)chlorofluoro- l l—hydroxy-l 7—methoxycarbonyl-
,13,l6-trimethyloxo-6,7,8,9,10,1 l ,12,13,l4,15, l6, l7-dodecahydro-3H~cyclopenta—
[a]phenanthrenyl ester.
U82010166671 discloses a medicament comprising an antimuscarinic agent, a beta;-
agonist and a corticosteroid. The examples of this application contain glycopyrronioum,
formoterol fumarate and mometasone furoate.
US7439393 discloses n hanolamine tives for the treatment of
respiratory diseases. The use of such compounds in combination therapy with other
therapeutic agents is also disclosed.
U820080041369 discloses propellant-free aerosol formulations comprising inter alia
olodaterol, a corticosteroid such as budesonide, beclomethasone or fluticasone and an
anticholinergic such as tiotropium, oxitropium or ipratropium.
U820050239778 discloses medicament combinations comprising inter alia olodaterol
and at least one other active substance, such as a steroid.
USZOO80317862 ses medicaments comprising an antimuscarinic agent and a
corticosteroid for the ent of inflammatory or obstructive airways diseases. In
particular, this application discloses aerosol compositions comprising glycopyrronium
and mometasone e.
U820060069073 discloses a combination of glycopyrronium and one or
more steroids as
a second active substance.
W02005110402 ses medicaments comprising glycopyrrolate in combination with
betaz-agonist such as indacaterol maleate.
W020050749OO discloses a combination of an anticholinergic such
as glycopyrronium
and a long-acting beta-mimetic agent such as formoterol or salmeterol.
Thus, there is still a need to p suitable combinations comprising a beta t, an
olinergic agent and/or an inhaled corticosteroid that alleviate COPD.
PCT/G32012/000171
Hence, there still exits a need to formulate ceutical compositions cemprising a
beta agonist, an anticholinergic agent and an d corticosteroid exhibiting reduced
side effects and which can be administered once a day.
Objects of the Invention
The object of the present invention is to provide pharmaceutical compositions for
inhalation comprising one or more bronchodilators and an inhaled corticosteroid for
administration in the prevention or treatment of respiratory, inflammatory
or obstructive
airway disease.
Another object of the present invention is to e pharmaceutical compositions for
inhalation comprising one or more bronchodilators and an inhaled corticosteroid for
once
daily administration for the prevention or treatment of respiratory, inflammatory or
obstructive airway disease.
Yet another object of the present invention is to provide a process for preparing the
pharmaceutical compositions comprising one or more odilators and an inhaled
osteroid for administration in the prevention or ent of respiratory,
atory or obstructive airway disease.
A further object of the present invention is to provide a method for prophylaxis or
ent of COPD which comprises administering pharmaceutical compositions
comprising one or more bronchodilators and an inhaled corticosteroid.
Summag of the Invention
According to a first aspect of the t invention, there is provided a pharmaceutical
composition comprising glycopyrrolate and a betaz-agonist.
Preferably the ition further comprises one or more inhaled corticosteroids.
PCT/GBZOlZ/000171
According to a second aspect of the present invention, there is provided a pharmaceutical
composition comprising glycopyrrolate and vilanterol.
According to a third aspect of the present invention, there is provided a pharmaceutical
composition comprising glycopyrrolate and olodaterol.
According to a fourth aspect of the present invention, there is provided a ceutical
composition comprising yrrolate and cannoterol.
According to a fifth aspect of the present invention, there is ed a ceutical
composition comprising glycopyrrolate, olodaterol and fluticasone, especially an ester of
fluticasone, in particular fluticasone furoate.
According to a sixth aspect of the present invention, there is provided a pharmaceutical
composition comprising glyc0pyrroiate, olodaterol and mometasone, eSpecially an ester
of mometasone, in particular mometasone fiiroate.
According to a seventh aspect of the present invention, there is provided a pharmaceutical
composition comprising glyc0pyrrolate, erol and asone, ally an ester of
fluticasone, in particular fluticasone furoate.
According to a eighth aspect of the present invention, there is provided a pharmaceuticai
composition comprising glycopyrrolate, fomoterol and fluticasone, especially an ester of
fluticasone, in particular fluticasone furoate.
According to a ninth aspect of the present invention, there is provided a pharmaceutical
ition comprising glycopyrrolate, indacetrol and fluticasone, eSpecially an ester of
sone, in particular sone furoate.
According to a tenth aspect of the present invention, there is provided a process for
preparing the pharmaceutical compositions described above.
W0 2012/1 10770
According to a eleventh aspect of the present invention, there is provided a method for
prophylaxis or treatment of asthma, COPD or a related respiratory disorder which
comprises administering a pharmaceutical itions described above.
According to a twelfth aspect of the present invention there is provided a use in
treating
disorders or conditions that respond to, or are prevented,
ameliorated or eliminated by,
the administration of pharmaceutical compositions described
above.
Detailed ption of the Invention
As discussed above, the selection of a c betag-agonist,
anticholinergic agent and
d corticosteroid (lCS) plays a
very important role in formulation of fixed dose
combinations.
The present invention thus provides pharmaceutical compositiOns for inhalation
comprising or consisting of glycopyrrolate, a betag-agonist, and an inhaled corticosteroid.
In one embodiment, there is provided a pharmaceutical composition for tion
sing or consisting of:
(a) yrrolate;
(b) a betag—agonist ed from the group consisting of carmoterol, formoterol,
indacaterol, olodaterol, vilanterol; and, optionally, when the LABA is selected
from formoterol, indacaterol, olodaterol, vilanterol;
(c) an inhaled corticosteroid (1C8) ed from the
group consisting of fluticasone,
mometasone;
preferably wherein (a), (b) and (c) are formulated for simultaneous, separate or sequential
administration; and provided that the composition does not comprise glycopyrrolate,
sone furoate and indacaterol maleate or formoterol fumarate.
A particularly preferred pharmaceutical composition of the
present invention comprises,
or consists of, (a) glycopyrrolate (b) indacaterol and (c) fluticasone (especially
fluticasone furoate).
A further ularly preferred pharmaceutical composition of the present invention
comprises, or consists of, (a) glycopyrrolate, (b) formoterol and (c) fluticasone
(especially fluticasone fiiroate).
A further particularly preferred pharmaceutical composition of the present invention
comprises, or consists of, (a) yrrolate (b) vilanterol and (c) asone
(especially
fluticasone fiiroare).
A further particularly preferred pharmaceutical ition of the present invention
comprises, or consists of, (a) glycopyrrolate, (b) olodaterol and (c) sone
(eSpecially
fluticasone furoate).
A still further particularly preferred pharmaceutical composition
of the present ion
comprises, or consists of, (a) yrrolate, (b) olodaterol and (c)
mometasone.
In an alternative preferred embodiment of the invention, there is provided a
ceutical composition comprising or consisting of glycopyrrolate and a beta;-
agonist.
In a still further preferred embodiment of the invention, there is provided a
pharmaceutical composition comprising or consisting of (a) yrrolate; and
(b) a
betaz-agonist selected from the group consisting of carmoterol, olodaterol, vilanterol;
preferably wherein (a) and (b) are formulated for simultaneous, separate or sequential
administration.
W0 2012,11 10770 ZO12/000171
A particularly preferred pharmaceutical composition of the
present invention comprises,
or consists of, (a) yrrolate and (b) vilanterol.
A further particularly preferred pharmaceutical composition of the present invention
comprises, or ts of, (a) glycopyrrolatc and (b) olodaterol.
A still further particularly preferred pharmaceutical composition of the
present invention
comprises, or consists of, (a) glycopyrrolate and (b) carmoterol.
Our inventors have found that the above-mentioned ceutical compositions are
effective for treating inflammatory and/or obstructive diseases of the respiratory
tract,
particularly asthma or chronic obstructive pulmonary disease (COPD).
Furthermore, the ceutical compositions of the present invention advantageously
provide a rapid onset of action, longer duration of action and improved control of
obstructive or inflammatory airway diseases, or reduction in the bations of the
diseases.
Also, the pharmaceutical compositions of the present invention advantageously reduce
the risk of undesirable side effects as compared to the repeated
exposure of the steroid
alone involved in the treatment of inflammatory or ctive airways diseases.
Another advantage of the pharmaceutical compositions of the
present invention is that the
invention facilitates the treatment of an obstructive and inflammatory airway e with
a single medicament.
Further the pharmaceutical itions of the present invention provide for the
administration of combination ies by use of a single inhaler for patients who
currently have to make use of multiple inhalers. By way of example, patients may
administer ceutical compositions of the present invention from
a single inhaler
instead of administering from three different inhalers, one for corticosteroid, one for
WO 10770
anticholinergic and one for a long acting betaz—agonist. This is particularly important in
case of elderly patients who may get confiised between the inhalers and who also
suffer
from several other medical conditions such as heart disease and arthritis, and are
receiving multiple other tions.
In a preferred embodiment, the pharmaceutical
compositions of the present invention are
formulated for once daily administration.
The pharmaceutical compositions of the
present invention comprise glycopyrrolate. The
word “glycopyrrolate” can be interchangeably used with “glycopyrronium”.
Glycopyrrolate belongs to the class of quaternary ammonium anticholinergic
drugs and
antagonizes the neurotransmitter choline at its muscarinic receptors. This effect
leads to a considerable smooth muscle tion ing in
a prolonged bronchodilating
effect. More specifically it inhibits acetylcholine binding to M3 muscarinic receptors
thereby ting bronchoconstriction.
Glycopyrrolate is a quatemary ammonium salt. Suitable counter ions are
ceutically acceptable counter ions including, for example, e, chloride,
bromide, iodide, e, sulfate, phosphate, formate, acetate, trifluoroacetate,
propionate,
butyrate, lactate, citrate, tartrate, malate, maleate, succinate, te,
p-chlorobenzoate,
diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, oxybenzoate, l-
hydroxynaphthalene~2-carboxylate, 3-hydroxynaphthalenecarboxylate,
methanesulfonate and benzenesulfonate. A particularly preferred salt of
glycopyrrolate is
the bromide salt thereof. The bromide salt of glycopyrrolate is chemically known
as {3-
[(Cyclopentyl-hydroxyphenylacetyl) oxy]—l, l-dimethylpynrolidinium bromide}.
Glycopyrrolate has two centers of asymmetry (chiral centers), and can exist in four
stereoisometric forms namely (3R, 2'R)-, (38, 2'R)-, (3R, 2'S)- and
(38, 2‘8), i. e. , two
enantiomeric pairs of diastereomers. The two di- astereomer
pairs have been ted
from one another. Commercially available formulations of
yrrolate contain both
the (R, S)~glycopyrrolate and (S, R)-glycopyrrolate enantiomers.
W0 2012A 10770
Glycopyrrolate is currently available marketed in the form of oral tablets for adjunctive
therapy in the treatment of peptic ulcer, as an injectable for therapy in the treatment of
peptic ulcer and as a preoperative antimuscarinic to reduce secretions and as a
capsule for
reducing chronic severe drooling in patients aged between 3 to 16
years with neurologic
conditions associated with problem drooling.
Glycopyrrolate also prevent the effects resulting from passage of es through the
parasympathetic . This action results from their ability to inhibit the action of
ransmitter acetylcholine by blocking its g to muscarinic cholinergic
ors. Further, inhaled glycopyrrolate ts low systemic tion, and
therefore is not associated with typical systemic antimuscarinic
adverse effects.
According to the present invention, glycopyrrolate may be t in an amount of from
about 50mcg to about ZOOmcg.
Bronchodilators used according to the present invention may be beta-agonists and/or
anticholinergics. ing to the t invention, beta agonists may comprise, one or
more, short acting beta agonist(s), long acting beta agonist(s) and/or ultra long acting
beta
agonist(s).
In addition to glycopyrrolate, the pharmaceutical compositions
of the present invention
further comprise a beta2~agonist, preferably selected from the group comprising
erol, formoterol, indacaterol, olodaterol, vilanterol.
Carmoterol is chemically known as 8—hydroxy-5 - (l-hydroxy(N—(2-(4-
methoxyzphenyl) -l-methyl:ethyl) amino)ethyl)-2 (lH)-quinolinone. erol is a
long acting betaz-agonist characterized by having a rapid onset of action, prolonged
duration of action and also having a high selectivity
towards the beta; adrenoreceptor.
Furthermore, carmoterol is more potent than other LABAs such as formoterol and
salmeterol. A particularly preferred pharmaceutically acceptable salt of carmoterol
W0 2012/1 10770 PCT/GBZ012/000171
carmoterol hydrochloride. According to the present invention,
carmoterol may be present
in an amount of from about lmcg to about 4mcg.
erol is chemically known as hydroxy[(1RS)-l-hydroxy[[(lRS)-2~(4—
methoxyphenyl)-lmethylethyl]-amino] ethyl] formanilide. Formoterol is a selective
LABA. Formoterol exhibits a quick onset of action (1-3 minutes) which
helps to achieve
an immediate therapeutic response. Furthermore formoterol exhibits a long duration of
action of more than 12 hours. A particularly preferred pharmaceutically
acceptable ester
of formoterol is fonnoterol fumarate. A particularly preferred pharmaceutically
acceptable ester of formoterol is formoterol fumarate dihydrate. According to the
present
ion, formoterol may be present in an amount of from about 12 to about 24mcg,
preferably about 24mcg.
Indacaterol is chemically known as (R)-5—[2~[(5,6-Diethyl-2,3.dihydro-1H—inden-2—
yl)amino]-l-hydroxyethyl]hydroxyquinolin-2(lilo-one is a uItra~Iong acting betaz-
agonist. Indacaterol has a fast onset of action which is r to that of formoterol and
faster than that of salmeterol. rmore, indacaterol exhibits a longer duration of
action than salmeterol as well as has greater cardiovascular safety
margin as compared to
salmeterol and erol. A ularly preferred pharmaceutically
acceptable salt of
indacaterol is indacterol maleate. According to the present ion, indacaterol may be
present in an amount of from about 25mcg to about 800mcg.
Olodaterol is chemically known as 6-hydroxy—8-K1R);l-hydroxy~2-{[2-(4~
methoxyphenyl)— l , l-dimethylethyl]amino]ethyl]~2H—1,4—benzoxazin—3(4H)- one. A
particularly preferred ceutically acceptable salt of olodaterol is olodaterol
hydrochloride monohydrate. According to the present invention, olodaterol may be
present in an amount of from about 3mcg to about SOmcg.
Vilanterol is chemically known as 4-{(l R)[(6- {2-[(2,6—
dichlorobenzyl)oxy]ethoxy}hexyl)amino]-l-hydroxyethyl}(hydroxymethyl)phenol is
a long acting beta2-agonist. A particularly preferred pharmaceutically acceptable
salt of
W0 2012/1 10770
vilanterol is vilanterol trifenatate. According to the present invention, vilanterol may be
present in an amount of from about 3mcg to about SOmcg.
In addition to glycopyrrolate and a betaz—agonist, the pharmaceutical
compositions of the
present invention may also comprise a corticosteroid; preferably selected from the
group
consisting of mometasone, fluticasone.
Fluticasone is currently cially available as a furoate salt and
a propionate salt.
Fluticasone furoate is a novel corticosteroid which ntially
overcomes the potential
side effects that are generally produced by the use of conventional corticosteroids.
Moreover fluticasone furoate exhibits a 1.7 times higher binding affinity for the
human
glucocorticoid receptor as compared to that of fluticasone propionate and also provides
prolonged protection up to 26 hours against airway hyperresponsiveness as compared to
fluticasone propionate. asone furuoate has a longer duration of action with an
ation half life of 15.1 hrs.
Fluticasone e is a synthetic fluorinated corticosteroid that
has been developed as an
asal treatment for patients with symptoms of rhinitis and has
an enhanced affinity
towards the glucocorticoid receptor. Further, fluticasone furoate has greater potency than
other ally used corticosteroids such as mometasone furoate, budesonide,
fluticasone
propionate, ciclesonide for the glucocorticoid receptor and against the proinflammatory
transcription factors nuclear factor KB (NF-KB), tion protein-l, and tumor necrosis
~ induced interleukin-8 cytokine production. Chronic inflammation which is
commonly ated with asthma is d by fluticasone furoate.
Particularly preferred phannaceutically acceptable esters of fluticasone are fluticasone
furoate and fluticasone propionate, most preferably fluticasone e.
According to the
present invention, fluticasone furoate may be present in an amount of from about 25mcg
to about 800mcg.
W0 2012/1 10770 PCT/G32012/000171
Mometasone furoate is chemically known as (11[B], l6[a])-9, 21-dichloro-l7-[(2-
furanylcarbonyl) oxy]-1 1-hydroxy-l6-methylpregna-l,4-diene-3,20-dione. Mometasone
furoate is a synthetic l7-heterocyclic corticosteroid and ts
a long duration of action
A particularly preferred pharrnaceutically able ester of mometasone is
mometasone
furoate. According to the present invention, mometasone e may be present in an
amount of from about 400mcg to about 800mcg.
As used herein the terms “glycopyrronium”, “glycopyrrolate”, "fluticasone e”,
“mometasone furoare”, “carmoterol”, “olodaterol, “vilanterol’, terol” and
“indacaterol” are used in broad sense to include not only “glycopyrronium”,
“glycopyrrolate” “fluticasone furoate” “mometasone furoare”, “carmoterol”, “clodaterol,
“vilanterol’, ”formoterol” and “indacaterol” per se but also their pharmaceutically
acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable
hydrates, pharmaceutically acceptable enantiomers, pharrnaceutically acceptable
derivatives, pharmaceutically acceptable polymorphs, ceutically acceptable
prodrugs, etc.
In on to active ceutical ingredients, the pharmaceutical compositions
of the
present ion typically comprise one or more pharmaceutically acceptable eXcipients.
The active ingredients may be used as separate formulations
or as a single combined
formulation. When combined in the same formulation, it will be appreciated that the
active ingredients must be stable and compatible with each other and the other
components of the formulation.
The pharmaceutical compositions of the present invention are formulated for inhalation
and may therefore be administered by
any suitable methods used for delivery of the drugs
to the respiratory tract. For example, the ition of the present invention
may be in
the form of an aerosol composition, a nasal
spray, nasal drops or an insufflation powder.
Such aerosol itions may be administered by
any conventional means, for example
using a metered dose inhaler (MDI), dry powder r (DPI) 0r nebulizer.
PCT/G32012/000171
The various dosage forms according to the present invention may comprise
carriers/excipients suitable for formulating the same.
In one embodiment, the ceutical compositions of the
present invention are in a
form suitable for administration by a MDI, for example, in the form of an aerosol
composition. Such compositions may comprise one or more pharmaceutically
acceptable
excipients, in particular selected from the group of HFC/HFA propellants, co—solvents,
bulking agents, non-volatile ents, buffers/pH adjusting agents, surface active
agents, preservatives, complexing agents, or combinations thereof.
Suitable pr0pellants are those which, when mixed with the cosolvent(s), form a
homogeneous propellant system in which a eutically ive amount of the
medicament can be dissolved. The I—IFC/HFA propellant must be toxicologically safe
and must have a vapor pressure which is suitable to enable the ment to be
administered via a pressurized MDI.
According to the present invention, the HFC/HFA propellants may comprise, one or more
of l,l,1,2-tetrafluoroethane (HFA—134(a)) and 1,1,l,2,3,3,3,-heptafluoropropane (HFA-
227), HFC-32 (difluoromethane), HFC-l43(a) (l,l,l-trifluoroethane), HFC~134 (l,l,2,2—
tetrafluoroethane), and HFC~152a (l,l-difluoroethane) or combinations thereof and such
other propellants which may be known to the
person having a skill in the art.
In the context of the t invention, the term “co-solvent”
means any t which is
miscible in the ation in the amount desired and which, when added provides
formulation in which the ment can be dissolved. The function of the co-solvent
to increase the solubility of the medicament and the excipients in the formulation.
According to the present invention, the co-solvent may comprise one or more of, C2- C6
tic alcohols, such as, but not limited to, ethyl alcohol and isoprOpyl alcohol; glycols
such as but not limited to propylene glycol, polyethylene glycols, opylene glycols,
glycol ethers, and block copolymers of oxyethylene and oxypropylene; and other
substances, such as, but not limited to, ol, polyoxyethylene alcohols, and
polyoxyethylene fatty acid esters; hydrocarbons such as but not limited to
n-propane, n~
, isobutane, n-pentane, iso-pentane,
neo-pentane, and n-hexane; and others such as
but not d to diethyl ether and combinations
thereof.
le surfactants which may be employed in an aerosol ition of the
invention include those which may serve to stabilize the on formulation and
improve the performance of valve systems of the metered dose inhaler. Preferred
surfactants e one or more ionic and/or
non~ ionic surfactants. Examples of suitbale
surfactants include, but are not limited to, oleic acid, sorbitan trioleate, lecithin,
isopropylmyristate, tyloxapol, nylpyrrolidone, polysorbates such
as polysorbate 80,
vitamin E-TPGS, and macrogol hydroxystearates
such as macrogol~15~hydroxystearate
and combinations thereof.
In the context of the present invention, the
term “non~volatile component” refers to the
suspended or ved constituents of the pharmaceutical composition that
would remain
after evaporation of the solvent(s)
present.
According to the present invention, the n0n~volatile component may comprise one
more of monosaccharides such as, but not limited
to, glucose, ose; disaccharides
such as lactose, maltose; oligosaccharides and polysaccharides
such as, but not limited to,
dextrans; polyalcohol such as, but not limited to, glycerol, ol, mannitol, xylitol;
salts such as, but not limited to, potassium chloride, magnesium chloride, magnesium
sulphate, sodium chloride, sodium citrate, sodium phosphate, sodium hydrogen
phosphate, sodium hydrogen carbonate, potassium citrate, ium phosphate,
potassium en phosphate, potassium hydrogen carbonate, calcium
carbonate and
calcium chloride and combinations thereof.
Suitable bulking agents may be employed in the pharmaceutical compositions of the
invention, in particular aerosol compositions that are intended for
administration using an
MDI. The bulking agent may comprise one or more of saccharides, including
PCT/G82012/000171
monosaccharides, disaccharides, polysaccharides and sugar alcohols such as arabinose,
glucose, se, ribose, mannose, e, terhalose, lactose, maltose, starches, dextran
or mannitol and combinations f.
Suitable buffers or pH adjusting agents may be employed in the pharmaceutical
compositions of the ion, in particular aerosol compositions that are intended for
administration using an MDI. The buffer or the pH adjusting
agent may comprise one or
more of organic or inorganic acids such as, but not limited to, citric acid, ascorbic acid,
hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid and combinations thereof.
Suitable preservatives may be employed in in the pharmaceutical itions of the
invention, in particular aerosol compositions that are intended for administration using
MDI, to t the formulation from contamination with pathogenic bacteria. The
preservative may comprise one or more of benzalkonium chloride, benzoic acid,
benzoates such as sodium benzoate and such other preservatives which
may be knowu to
the person having a skill in the art and combinations thereof.
Suitable complexing agents may be empioyed in the pharmaceutical
itions of the
invention, in particular aerosol compositions that are intended for administration using
MDI, capable of forming complex bonds. The complexing agent
may comprise one or
more of, but not d to, sodium EDTA or um EDTA and combinations thereof.
In one embodiment, the pharmaceutical compositions of the
present invention are in a
form suitable for administration by a dry powder inhaler (DPI).
The pharmaceutically acceptable excipients suitable for dry powder inhalation
according
to the present invention may be selected from suitable carriers which include, but
are not
limited to, sugars such as glucose, saccharose, lactose and se, es or starch
derivatives, oligosaccharides such as dextrins, cyclodextrins and their derivatives,
polyvinylpyrrolidone, alginic acid, tylose, silicic acid, cellulose, cellulose derivatives (for
example cellulose , sugar ls such as mannitol or sorbitol, calcium carbonate,
calcium phosphate, etc. lactose, lactitol, dextrates, , dextrose, maltodextrin, saccharides
including monosaccharides, disaccharides, polysaccharides; sugar alcohols such as
arabinose, , mannose, sucrose, trehalose, maltose, dextran and combinations
thereof.
In an alternative embodiment, the pharmaceutical compositions of the
t ion
are in a form suitable for administration by nebulization.
Nebulization y has an advantage over other inhalation therapy, since it is easy to
use and does not require co-ordination or much effort. It also works much more rapidly
than medicines taken by mouth. Such compositions may comprise le ents
such as one or more, but not limited to, ty agents, pH regulators, and chelating
agents in a suitable vehicle.
Examples of suitable isotonicity-adjusting agents include sodium chloride, potassium
chloride, zinc chloride, calcium chloride and mixtures thereof. Other isotonicity-
adjusting agents may also include, but are not limited to, mannitol, ol, and se
and mixtures thereof.
The pH of pharmaceutical compositions of the invention
may be adjusted by the addition
of one or more pH regulators such as pharmacologically acceptable acids.
Phannacologically acceptable inorganic acids or organic acids may be used for this
purpose. Examples of preferred inorganic acids include one or more acids selected from
the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid
and phosphoric acid and combinations thereof. Examples of particularly suitable organic
acids include one or more acids selected from the
group consisting of ic acid, citric
acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic
acid and propionic acid and ations thereof.
Examples of suitable chelating agents for use in a pharmaceutical compositions of the
invention include editic acid (EDTA) or a salt thereof,
e.g. sodium EDTA or disodium
EDTA dihydrate (sodium edetate), and mixtures of such compounds.
PCT/G82012/000171
In addition to the excipients such as isotonicity-adjusting agents, pH regulators, chelating
agents covered under nebulization therapy, the dosage forma as nasal spay and nasal
drops may comprise thickening agents.
es of suitable thickening agents may for use in a pharmaceutical itions of
the invention include cellulose derivatives (for example cellulose ether) in which the
cellulose-hydroxy groups are partially etherized with lower unsaturated aliphatic alcohols
and/or lower unsaturated aliphatic oxyalcohols (for example methyl cellulose,
ymethyl cellulose, hyd’roxypropylmethylcellulose), gelatin, polyvinylpyrrolidone,
tragacanth, ethoxose (water soluble binding and thickening agents on the basis of ethyl
cellulose), alginic acid, polyvinyl l, polyacrylic acid, pectin and equivalent agents.
Should these substances contain acid , the corresponding physiologically
acceptable salts may also be used.
In addition to the entioned excipients, one or more anti-microbial preservative
agents may also be added to the pharmaceutical compositions of the invention, in
particular for dose es.
In an alternative embodiment, the composition according to the present invention
may be
included in one or more suitable containers provided with means enabling the application
of the contained formulation to the respiratory tract.
Where the ceutical compositions of the invention are in the form of a powder for
inhalation and are intended to be administered by a DPI, it may be encapsulated in
capsules of gelatin or HPMC, or in blisters. In an alternative embodiment, the dry
powder may be contained as a reservoir either in a single dose or multi-dose dry powder
inhalation device. In a further alternative embodiment, the powder for tion may be
suspended in a suitable liquid vehicle and packed in an aerosol container along with
suitable propellants or mixtures thereof. In still a further alternative ment, the
powder for inhalation may be dispersed in a suitable gas stream to form an aerosol
composition.
Where the pharmaceutical compositions of the invention are in the form of an aerosol
composition for administration using an MDI, it may be packed in plain aluminium cans
or SS (stainless steel) cans or any such cans suitable for MDI delivery. Some aerosol
drugs tend to adhere to the inner surfaces, i.e., walls of the cans and valves, of the MDI.
This can lead to the patient getting cantly less than the prescribed amount of the
active agent upon each activation of the MDI. Such cans may be suitably d to avoid
any adherence of the active on the walls thereof using techniques known in the art, for
e coating the inner surface of the container with a suitable polymer can reduce this
adhesion problem. Suitable coatings include fluorocarbon c0polymers such as FEP~PES
(fluorinated ethylene propylene and polyethersulphone) and PFA-PES
(perfluoroalkoxyalkane and polyethersulphone), epoxy and ethylene. Alternatively, the
inner surfaces of the cans may be anodized, plasma treated or plasma coated.
Where the pharmaceutical. compositions of the invention are in the form of nasal sprays
and nasal drops for administration into the nasal es it may be done by means of a
dropper (or pipette) that includes a glass, plastic or metal dispensing tube. Fine droplets
and Sprays can be provided by an intranasal pump dispenser or squeeze bottle as well
knOWn in the art.
The pharmaceutical compositions of the present ion may further se, in
addition to those ceutically active ingredients detailed above, one or more
active(s) selected from the group comprising of , stamines, antiallergics or
leukotriene antagonists, or their ceutically acceptable salts, solvates, tautomers,
derivatives, enantiomers, isomers, hydrates, gs or polymorphs thereof.
The pharmaceutical compositions of the t invention comprise glycopyrrolate, a
betaz-agonist and, optionally, a corticosteroid. These active ingredients are formulated
for simultaneous, separate or sequential administration. When the active ingredients are
administered sequentially, either glycopyrrolate the long acting betaz-agonist, or where
present, the corticosteroid, may be administered first. When administration is
simultaneous, the active ingredients may be administered either in the same or different
PCT/GBZOIZ/000171
pharmaceutical compositions. Adjunctive therapy, ire. where one active ient is
used as the y treatment and the other active ingredient(s) is/are used
to assist that
y ent is also an embodiment of the present invention.
According to a further embodiment of the invention, there is provided a product
comprising (a) glycopyrrolate; (b) a betayagonist selected from the group comprising
carmoterol, olodaterol, vilanterol; as a combined preparation for simultaneous, separate
or sequential use for treatment and /or prevention of respiratory, inflammatory or
obstructive airway disease
According to a another embodiment of the invention, there is provided a product
comprising (a) glycopyrrolate; (b) a betaz-agonist selected from the group comprising
olodaterol, vilanterol, erol, indacaterol (c) a corticosteroid selected from the
group
consisting of fluticasone, mometasone, as a combined preparation for simultaneous,
separate or sequential use for treatment and /or prevention ofrespiratory, inflammatory or
obstructive airway disease
Compositions for use according to the present invention may be presented in a pack or
dispenser device which may contain one or more unit dosage forms containing the active
ingredients. These may for example, comprise metal or plastic foil, such as a blister
pack. Where compositions are intended for administration
as two separate compositions
these may be presented in the form ofa twin pack.
ceutical compositions may also be ibed in “patient packs” containing the
whole course of treatment in a single package. The inclusion of a package insert has
been shown to e patient compliance with the prescribing physician’s instructions.
According to a further embodiment of the t invention, there is provided a patient
pack comprising at least one active ingredient of the combination according to the
invention and an ation insert containing ions to use the combination of the
ion. In one embodiment, the present invention provides a fixed dose combination.
The pharmaceutical compositions of the
present invention may be conveniently presented
in unit dosage form and
may be prepared by any of the methods well known in the art.
le s include the step of bringing into association
the active ingredients with
a carrier which constitutes one or more phannaceutically acceptable excipients. In
general, compositions may be prepared by uniformly and intimately bringing into
association the active ingredients with one or more liquid carriers
or finely divided solid
carriers, or both. It will be iated that when the active ingredients
are administered
independently, each may be administered by a different means.
The t invention also es a
process to manufacture the itions according
to the present invention.
In one embodiment, the present invention provides
a process of preparing pharmaceutical
compositions for administration by a metered dose r, which process comprises
ng a phannaceutically acceptable carrier or excipient with one or more active
pharmaceutical ingredients of the invention and a propellant, and thereafter
transferring
the composition to a suitable container, preferably
a pre-crimped can.
In another embodiment, the invention provides
a process of preparing a pharmaceutical
compositions for administration by dry powder inhalation, which process comprises
ng of a pharmaceutically acceptable r or excipient with one or
more active
pharmaceutical ients of the invention and providing the composition as a dry
powder.
In a further embodiment, the invention provides
a process of preparing pharmaceutical
compositions for administration by nebulisation, which process comprises dissolving the
drugs, optionally chelating agents, osmotic/isotonicity adjusting agents and
any other
suitable ingredients in the vehicle and adjusting the pH using
a suitable pH adjusting
agent
W0 2012/1 10770 PCT/G32012/000171
In a further embodiment, the invention also es
a method for the prevention and/or
treatment of a respiratory,
inflammatory or ctive airway disease, in particular
chronic obstructive pulmonary disease, in a mammal, such as a human, which method
comprises administration of a therapeutically ive amount of pharmaceutical
compositions according to the present ion.
The present invention also provides pharmaceutical compositions according to the
present invention for use in preventing and/or treating disorders or conditions that
d to, or are prevented, ameliorated or eliminated by, the administration one or
more bronchodilators and an inhaled corticosteroid (ICS), such as a atory,
inflammatory or obstructive airway disease, in particular chronic obstructive pulmonary
disease.
The following examples are for the
purpose of illustration of the invention only and are
not intended in any way to limit the scope of the present invention.
Ingredients Qty ISpray
Process:
1) Fluticasone fiJroate, Glycopyrronium and Tiotropium were homogenized with
part
quantity ofHFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into imped
aluminum cans.
Process:
1) Fluticasone furoate, Indacaterol and GlyCOpyrronium were homogenized with lactose
and pan quantity ofHFA.
2) The suspension obtained in step I was transferred to the mixing vessel where
remaining ty of HFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Fluticasone Furoate 50 meg
Glycopyrronium 50 meg
4. PEG400/1000 0.3% of total
fonnulation
. PVP K 25 0.001% oftotal
formulation
HFA134A OR HFA227 _
Process:
1) PVP was dissolved in PEG and part quantity of HFA] 34A or HFA227.
W0 2012/1 10770
2) The solution obtained in Step 1 was erred to a mixing vessel.
3) Fluticasone furoate, Indacaterol and Glycopyrronium were homogenized with
a part
quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
) The resulting total su3pension was mixed, recirculated and filled in into imped
aluminum cans.
Example 4
-20% of total
formulation
1% of total
formulation
Process:
1) Glycerol was dissolved in ethanol and required quantity ofHCl was added.
2) Fluticasone furoate, Indacaterol and Glycopyrronium were dissolved in the solution
obtained in step 1.
3) The resulting solution was erred to the mixing vessel where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into imped
aluminum cans.
PCT/G32012/00017l
Example 5
4. Ethanol 15-20% of total
formulation
HCL ( 0.08N) pH 2.5-3.5
Process:
1) Required quantity ofHCl was added to ethanol.
2) Fluticasone furoate, Indacaterol and Glycopyrronium were ved in the on
obtained in step 1.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, recirculated and filled in into imped
aluminum cans.
Example 6
Sr. No. Ingredients Qty ISpray
1. Fluticasone Furoate 50 mcg
2. Glycopyrronium 50 meg
-lndacaterol3. 50 meg
-4. Ethanol 15-20% of total
formulation
-5. Glycerol 1% of total
formulation
Citric acid anhydrous
7. HFA134a q.s.
Process:
1) Citric acid anhydrous and glycerol were dissolved in ethanol.
2) Fluticasone furoate, Indacaterol and Glycopyrronium were dissolved in the solution
obtained in step (1).
3) The solution obtained in step (2) was transferred to the main mixing vessel where it
was mixed with entire quantity ofHFAl34a.
4) The resulting suspension was mixed, recirculated and filled in into pre~crimped
aluminum cans.
Example 7
Qty/sway
4. Ethanol 15-20% of total
formulation
Citric acid anhydrous ~
. .
HFA134a
Process:
1) Citric acid ous was ved in ethanol.
2) Fluticasone furoate, Indacaterol and Glycopyrronium were dissolved in the on
obtained in step (1).
3) The solution ed in step (2) was transferred to the main mixing'vessel where it
was mixed with entire quantity of HFAl34a.
4) The resulting sion was mixed, recirculated and filled in into pre-crimped
aluminum cans.
PCT/G32012/000171
Example 8
Sr. No. Ingredients Qty ISpray
Fluticasone Furoate
Glycopyrronium 50 meg
4. Ethanol 1-2% of total
formulation
4a or HFA227 q.s.
Process:
1) Lecithin was dissolved in ethanol.
2) Glycopyrronium and Indacaterol were homogenized with
part quantity of HFA and
transferred to the mixing vessel.
3) Fluticasone e was homogenized with lecithin and ethanol.
4) The sion ed instep (3) was transferred to the main mixing vessel
where
the remaining quantity of HFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 9
. Ingredients Qty /Spray
Fluticasone Furoate 50 mcg
Glycopyrronium 50 meg
3 . lndacaterol 50 mcg
4. Ethanol 1-2% of total
formulation
. Oleic acid 0.02 — 5% of the
W0 2012/1 10770
Process:
1) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and Indacaterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) Fluticasone furoate was nized with oleic acid and ethanol.
4) The suspension obtained instep (3) was transferred to the main mixing vessel where
the remaining quantity of HFA was added;
) The resulting suspension was mixed, recirculated and filled in into pre~crimped
aluminum cans.
Example 10
Qty/mama
_Glycopyrronium bromide 0.050
Indacaterol Maleate 0.194
Lactose monohydrate IP/Ph.Eur/NF 24.656
1) Glycopyrronium, Indacaterol and asone furoate were sifted with a part quantity
of lactose.
2) The co-sifi of step I was then sifted with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
WO 10770
Example 11
Ingredients Qty / unit (mg)
Glycopyrronium bromide 0.100
Indacaterol Maleate 0.194
Fluticasone Furoate 0.200
Lactose monohydrate lP/Ph.Eur/NF 24.506
.000
Process:
1) GlyCOpyrronium, lndacaterol and Fluticasone furoate were sifted with a part quantity
of lactose.
2) The co-sifi of step 1 was then sifted with the remaining quantity of e and
blended.
3) The blend of step 2 was then filled in capsules.
Example 12
-Glycopyrronium e 0.200
2. Indacaterol Maleate 0.388
Fluticasone Furoate
Process:
l) Glycopyrronium, Indacaterol and Fluticasone furoate were sifted with a part quantity
of lactose.
2) The co-sift of step I was then sifted with the ing quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 13
Glycopyrronium 50 mcg
Formoterol
4A OR HFA227
Process:
1) Fluticasone furoate, Glycopyrronium and Formoterol were homogenized with part
quantity of HFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 14
1) Fluticasone e, Formoterol and Glycopyrronium were homogenized with lactose
and part quantity of HFA.
2) The suspension obtained in step I was transferred to the mixing vessel where
remaining quantity of HFA was added.
W0 2012/1 10770
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 15
O.3% of total
formulation
0.001% l
formulation
Process:
1) PVP was ved in PEG and part quantity of HFA134A or HFA227.
2) The solution obtained in Step 1 was transferred to a mixing vessel.
3) Fluticasone furoate, Formoterol and Glycopyrronium were homogenized with a part
quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
) The resulting total suspension was mixed, recirculated and filled in into pre~crimped
aluminum cans.
Example 16
Formoterol 24 meg
PCT/G32012/000171
. Glycerol 1% of total
formulation
uHCL ( 0.08N) pH 2.5 — 3.5
Process:
1) Glycerol was dissolved in ethanol- and required quantity of HCl was added.
2) Fluticasone furoate, Formoterol and Glycopyn'onium were dissolved in the solution
obtained in step 1.
3) The ing solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, ulated and filled in into pre-crimped
aluminum cans.
Example 17
4. l 15—20% of total
formulation
HCL ( 0.08N) pH 2.5-3.5
Process:
1) Required ty of HCl was added to ethanol.
2) Fluticasone fiiroate, Formoterol and Glycopyrronium were dissolved in the solution
obtained in step 1.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 18
Ingredients
Fluticasone Furoate
1-2% of total
formulation
Lecithin 0.02 of the API
HFA134a or HFA227
Process:
1) Lecithin was ved in l.
2) Glycopyrronium and Formoterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) Fluticasoen furoate was nized with lecithin and ethanol.
4) The su5pension obtained instep (3) was transferred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 19
_Fluticasone Furoate 50 mcg
Glycopyrronium 50 mcg
4. l 1-2% of total
formulation
S.‘ Oleic acid 0.02 — 5% of the
W0 2012/1 10770 2012/000171
Process:
1) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and Formoterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) asone furoate was nized with oleic acid and ethanol.
4) The suspension obtained instep (3) was transferred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 20
Qty/unit (mg)
2. Formeterol Fumarate dihydrate
Lactose monohydrate lP/Ph.Eur/NF
Process:
1) Glycopyrronium, Fonnoterol and asone furoate were sifted with a part quantity
of lactose.
2) The co-sifi of step 1 was then sifted with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 21
Qty/unit mg)
-Glycopyrronium bromide 0.010
Formeterol Fumarate dihydrate 0.006
3. Fluticasone Furoate 0.200
=4. Lactose drate IP/Ph.Eur/NF 24.694
Process:
1) Glycopyrronium, Formoterol and Fluticasone furoate were sifted with a part quantity
of lactose.
2) The co-sift of step 1 was then sifted with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 22
Qty I unlit (mg)
Glycopyrronium e
-Formeterol Fumarate ate2.
Lactose drate IP/Ph.Eur/NF 24.388
Process:
1) Glycopyrronium, Formoterol and Fluticasone furoate were sifted with a part quantity
of lactose.
2) The co-sifi of step I was then sifted with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 23
. . Ingredients
Process:
1) Fluticasone furoate, Glycopyrronium and Vilanterol were homogenized with part
quantity of HFA.
2) The suspension ed in step I was transferred to the mixing vessel where
remaining quantity of HFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
e 24
Sr. No. ients
Process:
1) Fluticasone furoate, Vilanterol and Glycopyrronium were homogenized with lactose
and pan quantity of HFA.
PCT/G32012/000171
2) The suspension obtained in step I was erred to the mixing vessel where
remaining quantity ofHFA was added.
3) The ing suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 25
Ingredients
Fluticasone Furoate
yrronium
PEG400/1000 0.3% of total
formulation
0.001% oftotal
formulation
HFA134A OR HFA227 q.s.
Process:
1) PVP was dissolved in PEG and part quantity ofHFA134A or HFA227.
2) The solution obtained in Step 1 was transferred to a mixing .
3) Fluticasone furoate, Vilanterol and Glycopyrronium were homogenized with a part
quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity of HFA was added.
) The resulting total suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 26
Sr. No. 1 Ingredients Qty /Spray
W0 2012/1 10770 PCT/G32012/000171
4. Ethanol 15-20% of total
formulation
ol 1% of total
formulation
-W__
Process:
1) Glycerol was dissolved in l and ed quantity of HCl was added.
2) Fluticasone furoate, Vilanterol and Glycopyrronium were dissolved in the on
obtained in step 1.
3) The resulting solution was transferred to the mixing vessel where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 27
Fluticasone Furoate 50 meg
4. Ethanel 154.0% of total
formulation
HCL ( 0.03m pH 2.5-3.5
Process:
1) Required quantity of HCl was added to ethanol.
2) Fluticasone furoate, Vilanterol and Glycopyrronium were dissolved in the solution
obtained in step I.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
W0 2012/1 10770
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 28
Ingredients Qty lSpray
_Fluticasone Furoate 50 mcg
GlyCOpyrronium 50 mcg
-M12.5 meg
Ethanol 1-2% of total
formulation
0.02 of the API
HFA134a or HFA227
q.s.
Process:
1) Lecithin was dissolved in ethanol.
2) Glycopyrronium and Vilanterol were homogenized with part quantity of HFA and
erred to the mixing .
3) Fluticasoen fiiroate was homogenized with lecithin and ethanol.
4) The suspension obtained instep (3) was transferred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suSpension was mixed, recirculated and filled in into pre-crimped
um cans.
Example 29
ESr. No. Qty /Spray
Glycopyrronium 50 meg
Vi [anterol 12.5 mcg
4. l 1-2% of total
formulation
Oleic acid 0.02 - 5% of the
HFA134a or HFA227 _
Process:
1) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and erol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) Fluticasoen furoate was homogenized with oleic acid and ethanol.
4) The sion obtained instep (3) was transferred to the main mixing vessel where
the remaining ty of HFA was added.
) The resulting suspension was mixed, recirculated and filled in into imped
aluminum cans.
Example 30
Process:
1) Glycopyrronium, Vilanterol Trifenatate and Fluticasone furoate were sified with
a part
quantity of lactose.
2) The co-sifi of step 1 was then sifted with the remaining quantity of lactose and
blended.
3) The blend ofstep 2 was then filled in capsules.
W0 2012/1 10770 PCT/G32012/000171
e 31
. Ingredients Qty / unit (mg)
Glycopyrronium bromide 0.010
2. Vilanterol atate 0.025
Lactose monohydrate lP/Ph.Eur/NF 24.675
Process:
1) Glycopyrronium, Vilanterol Trifenatate and Fluticasone furoate were sifted with
a part
quantity of lactose.
2) The co—sift of step 1 was then sifted with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 32
Sr. No. Ingredients Qty / unit (mg)
-Glycopyrronium bromide 0.200
Vilanterol Trifenatate 0.050
asone Furoate 0.400
_Lactose monohydrate IP/Ph.Eur/NF 24.350
-Total 25.000
Process:
i) Glycopyrronium, Vilanterol atate and Fluticasone furoate were sifted with a
part
quantity of lactose.
WO 10770 PCT/G32012/000171
2) The co-sifi of step 1 was then sifted with the remaining ty of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 33
Process:
1) Fluticasone furoate, Glycopyrronium and Olodaterol were homogenized with part
quantity ofHFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining quantity of HFA was added.
3) The resulting suspension was mixed, recirculated and filled in into preocrimped
aluminum cans.
Example 34
W0 2012/1 10770 PCT/GBZOlZ/00017l
Process:
1) asone fiJroate, Olodaterol and Glycopyrronium were homogenized with lactose
and part quantity of HFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining ty ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into imped
aluminum cans.
Example 35
Ingredients Qty ISpray
Fluticasone Furoate “
50 mcg
2. yrronium 50 meg
Olodaterol 5 mcg
4. PEG400/1000 0.3% of total
formulation
. PVP K 25 0.001% oftotal
formulation
_HFA134A OR HFA227 q.s.
Process:
1) PVP was dissolved in PEG and part quantity of HFA134A or HFA227.
2) The solution obtained in Step 1 was transferred to a mixing vessel.
3) Fluticasone furoate, Olodaterol and Glycopyrronium were homogenized with a part
quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
) The resulting total SUSpension was mixed, recirculated and filled in into imped
aluminum cans.
Example 36
Qty /Spray
-20% of total
formulation
Glycerol 1% of total
formulation
nHCL(0.08N) '
pH 2.5 - 3.5
-fi_q.s_
Process:
l) Glycerol was dissolved in ethanol and required ty of HCl was added.
2) Fluticasone furoate, Olodaterol and yrronium were dissolved in the solution
obtained in step 1.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, recirculated and filled in into pre—crimped
aluminum cans.
Example 37
Sr. No. ients Qty ISpray
Fluticasone Furoate 50 mcg
iGlycopyrronium 50 mcg
Olodaterol 5 meg
. Ethanol 15-20% of total
formulation
. HCL ( 0.08N) pH 2.5-3.5
HFA 134a
q.s.
PCT/G32012/000171
Process:
1) Required quantity of HCI was added to ethanol.
2) Fluticasone e, Olodaterol and Glycopyrronium were dissolved in the solution
obtained in step 1.
3) The resulting solution was transferred to the mixing vesse l where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into pre—crimped
aluminum cans.
Example 38
Ingredients
l. asone Furoate
Glycopyrronium
-3. Olodaterol
1-2% of total
formulation
0.02 of the API
_HFA 1 34a or HFA227
Process:
1) in was dissolved in ethanol.
2) Glycopyrronium and Olodaterol were homogenized with
part quantity of HFA and
transferred to the mixing vessel.
3) Fluticasone fiiroate was homogenized with lecithin and ethanol.
4) The suspension ed instep (3) was erred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suspensiOn was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 39
Sr. N0. ients Qty /Spray
1. Fluticasone Furoate
2. Glycopyrronium 50 mcg
3. Olodaterol 5 mcg
1—2% of total
formulation
. Oleic acid 0.02 —— 5% of the
6. HFAl34a or HFA227
q.s.
]) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and Olodaterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) Fluticasone furoate was homogenized with oleic acid and ethanol.
4) The suspension obtained instep (3) was transferred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
um cans.
Example 40
Sr. N0. Ingredients Qty/ unit (mg)
-Glycopyrronium bromide 0.050
Olodaterol ‘ 0.005
Lactose monohydrate IP/Ph.Eur/NF 24.845
WO 10770 PCT/G32012/000171
Process:
1) Glycopyrronium, Olodaterol and Fluticasone furoate were sifted with a part quantity of
lactose.
2) The co—sifi of step 1 was then sifted with the ing quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 41
Qty / unit (mg)
1. Glycopyrronium bromide
N Olodaterol -
Process:
1) GlyCOpyrronium, Olodaterol and Fluticasone furoate were sifted with a part quantity of
lactose.
2) The co—sifi of step 1 was then sifted with the remaining quantity of lactose and
3) The blend of step 2 was then filled in capsules.
Example 42
Qty/mm
Glycopyrronium bromide 0.200
Olodaterol 0.010
Lactose monohydrate IP/Ph.Eur/NF 24.390
Process:
1) Glycopyrronium, Olodaterol and Fluticasone furoate were sified with a part quantity of
lactose.
2) The co—sifi of step 1 was then sifted with the ing ty of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 43
Process:
1) sone furoate, Glycopyrronium and Olodaterol were homogenized with part
quantity of HFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining duantity of HFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre—crimped
aluminum cans.
Example 44
PCT/G32012/000171
Process:
1) Mometasone furoate, erol and Glycopyrronium were homogenized with lactose
and part quantity ofHFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 45
Qty ISpray
l. Mometasone furoate
2. Glycopyrronium
0.3% of total
formulation
0.001% of total
formulation
Process:
1) PVP was dissolved in PEG and part ty of HFA 134A or .
2) The solution obtained in Step 1 was transferred to a mixing vessel.
3) Mometasone furoate, erol and Glycopyrronium were homogenized with a part
quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
ing quantity of HFA was added.
) The resulting total suspension was mixed, recirculated and filled in into pre—crimped
aluminum cans.
W0 2012/1 10770 2012/000171
Example 46
Ingredients oJ' \U} "U 1a:"<
Mometasone furoate 400 mcg
Glycopyrronium 50 mcg
Olodaterol 5 meg
-Ethanol4. 15-20% oftotal
formulation -
. 1% of total
formulation
EHCL ( 0.08N) pH 2.5 — 3.5
Process:
1) Glycerol was dissolved in ethanol and required quantity of HCl was added.
2) Mometasone furoate, Olodaterol and Glycopyrronium were dissolved in the solution
obtained in step 1.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
um cans.
e 47
Sr. No. Ingredients
Glycopyrronium 50 meg
Olodaterol 5 meg
‘4. Ethanol 15-20% of total
formulation
HCL ( 0.08N) pH 2.5—3.5
Process:
1) ed quantity of HCl was added to ethanol.
2) sone furoate, Olodaterol and Glycopyrronium were dissolved in the solution
obtained in step 1.
3) The resulting solution was transferred to the mixing vessel Where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
um cans.
Example 48
Sr. No. Ingredients O‘3a"U3<4
-Mometasone furoate 400 mcg
Glycopyrronium 50 mcg
Olodaterol 5 meg
4. Ethanol 1—2% of total
formulation
_HFAl34a or HFA227 q.s
Process:
1) Lecithin was dissolved in l.
2) yrronium and Olodaterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) Mometasone furoate was homogenized with lecithin and ethanol.
4) The suspension obtained instep (3) was transferred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 49
Sr. No. Ingredients Qty /Spray
Oiodaterol 5 meg
4. 1-2% of total
formulation
. Oleic acid 0.02 —- 5% ofthe
_HFA134a or HFA227
Process:
1) Oleic acid was dissolved in ethanol.
2) yrronium and Olodaterol were homogenized with
part quantity of HFA and
transferred to the mixing vessel.
3) Mometasone furoate was homogenized with oleic acid and ethanol.
4) The suspension obtained instep (3) was erred to the main mixing vessel where
the remaining quantity ofHFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 50
Lactose monohydrate IP/Ph.Eur/NF 24.390
2012/000171
Process:
]) Glycopyrronium, Olodaterol and Mometasone furoate
were sified with a part quantity
of lactose.
2) The co—sift of step 1 was then sifted with the remaining quantity
of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 51
Qty / unit (mg)
1) Glycopyrronium and Vilanterol Trifenatate were sifted with
a part quantity of lactose.
2) The co—sifi of step I was then sified with the remaining quantity of
lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 52
. Ingredients
Process:
1) Glycopyrronium and Vilanterol Trifenatate were sifted with a
part quantity of lactose.
2) The co-sift of step I was then sifted with the remaining ty of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 53
Qty / unit (mg)
Glycopyrronium bromide 0.200
Vilanterol Trifenatate 0.050
Lactose monohydrate IP/Ph.Eur/NF 24.750
Process:
1) Glycopyrronium and Vilanterol Trifenatate were sified with a part quantity of lactose.
2) The co-sift of step 1 was then sified with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 54
Process:
1) yrronium and Vilanterol were homogenized with part quantity of HFA.
2) The sion obtained in step 1 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 55
Qty /Spray
50 meg
12.5 mcg
100% ofthe drug
q.s.
Process:
1) Vilanterol and Glycopyrronium were homogenized with lactose and
part quantity of
HFA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining ty of HFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
e 56
Sr. No. i Ingredients Oq E'53Nt<
l. Glyc0pyrronium 50 mcg
iVilanterol 12.5 mcg
i.PEG400/1000 0.3% of total
formulation
4. PVP K 25 0.001% of total
formulation
Process:
1) PVP was dissolved in PEG and part quantity of A or HFA227.
2012/000171
2) The solution obtained in Step 1 was transferred to a mixing vessel.
3) Vilanterol and Glycopyrronium were homogenized with a part quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
) The resulting total suspension was mixed, recirculated and filled in into
pre-crimped
aluminum cans.
Example 57
3. l 15-20% of total
formulation
4. Glycerol 1% of total
formulation
HCL ( 0.08N) pH 2.5 — 3.5
CEM—
Process:
1) Glycerol was dissolved in ethanol and required quantity of HCl was added.
2) Vilanterol and yrronium were dissolved in the solution obtained in
step 1.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, ulated and filled in into pre'crimped
aluminum cans.
Example 58
-Glycopyrronium 50 mcg
Ethanol 15-20% of total
HCL ( 0.08N) pH 2.5—3.5
Process:
1) Required quantity of HCl was added to ethanol.
2) Vilanterol and Glycopyrronium were dissolved in the on obtained in
step I.
3) The resulting solution was transferred to the mixing vessel where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
e 59
Qty/Spray
Glycopyrronium 50 meg
3. l 1-2% of total
formulation
HFAl34a or HFA227
Process:
1) Lecithin was dissolved in ethanol.
2) Glycopyrronium and erol were homogenized with part quantity of HFA and
transferred to the mixing .
3) The solution obtained in step (1) was homogenized with
part quantity ofHFA
4) The mixture obtained in step (3) was transferred to the main mixing vessel where the
remaining quantity ofHFA was added.
) The resulting suspension was mixed: recirculated and filled in into pre—erimped
aluminum cans.
Example 60
Qtv /Spray
l2 5 mcg
1-2°/o of total
formulation
Oleic acid 0.02 — 5% ofthe
HFA134a or HFAZZ’I
q.s.
Process:
1) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and Vilanterol were nized with part quantity of HFA and
transferred to the mixing vessel.
3) The on obtained in step (1) was homogenized with part quantity ofHFA
4) The mixture obtained in step (3) was transferred to the main mixing vessel where the
remaining quantity of HFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 61
Ingredients Qty / unit (mg)
Glycopyrronium bromide
Olodaterol ’
0.005
Lactose monohydrate Eur/NF 24.944
Process:
1) yrronium and Olodaterol were sified with a part quantity of lactose.
PCT/GBZOlZ/000171
2) The co-sifi of step 1 was then sifted with the remaining ty of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
e 62
Process:
1) Glycopyrronium and Olodaterol were sifted with a part quantity of lactose.
2) The co-sifi of step 1 was then sifted with the remaining quantity of lactose and
blended.
3) The blend of step 2 was then filled in capsules.
Example 63
HFA134A OR HFA227
Process:
1) Glycopyrronium and Olodaterol were homogenized with part quantity ofHFA.
2) The suspension obtained in step liwas transferred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 64
Glycopyrronium 100 mcg
100% ofthe drug
Process:
1) erol and Glycopyrionium were homogenized with lactose and
part quantity of
EPA.
2) The suspension obtained in step 1 was transferred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 65
Sr. No.
Glycopyrronium 100 mcg
Olodaterol 5 mcg ‘
3. PEG400/1000 0.3% of total
formulation
4. PVP K 25 0.001% oftotal
formulation
Process:
1) PVP was dissolved in PEG and part quantity of HFAl34A or HFA227.
2) The on obtained in Step 1 was transferred to a mixing vessel.
3) erol and Glycopyrronium were nized with a part quantity of HF‘A.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity of HFA was added.
) The resulting total suspension was mixed, ulated and filled in into pre-crimped
aluminum cans.
Example 66
Sr. No. ients Qty ISpray
_Glycopyrronium 100 mcg
3. Ethanol 15—20% of total
formulation
4. Glycerol 1%. oftotal
formulation
HCL ( 0.08N) pH 2.5 — 3.5
Process:
1) ol was dissolved in ethanol and required quantity of HCl
was added.
2) Olodaterol and Glycopyrronium were dissolved in the solution obtained in
step 1.
3) The resulting solution was transferred to the mixing vessel where HFA
was added.
4) The ing suspension was mixed, recirculated and filled in into pre—crimped
aluminum cans.
Example 67
Qty /Spray
_Glycopyrronium 100 mcg
Olodaterol 5 mcg
3. Ethanol 15-20% of total
formulation
. HCL ( 0.08N) pH 2.5~3.5
W0 2012/1 10770 PCT/G32012/000171
-EM_
Process:
1) Required quantity of HCl was added to ethanol.
2) Olodaterol and Glycopyrronium were dissolved in the solution obtained in
step 1.
3) The resulting solution was transferred to the mixingvessel where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into pre-crimped
um cans.
e 68
Ingredients Qty /Spray
1-2% of total
formulation
1) Lecithin was dissolved in ethanol.
2) Glycopyrronium and erol were homogenized with
part quantity of HFA and
transferred to the mixing vessel.
3) The solution obtained in step (I) was homogenized with part quantity ofHFA
4) The mixture obtained in step (3) was transferred to the main mixing vessel where the
remaining quantity ofHFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
2012/000171
Example 69
ients Qty ISpray
Glycopyrroniurn 100 mcg
3. Ethanol l~2% of total
formulation
4. Oleic acid 0.02 - 5% of the
Process:
1) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and Olodaterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) The solution obtained in step (1) was homogenized with part quantity ofHFA
4) The mixture obtained-in step (3) was transferred to the main mixing vessel where the
remaining quantity of HFA was added.
) The resulting suspension was mixed, recirculated and filled in into pre—crimped
aluminum cans.
Example 70
Ingredients Qty / unit (mg)
1. ‘ yrronium
bromide
2. l Cannoterol Hydrochloride
e monohydrate IP/Ph.Eur/NF
Process:
1) Glycopyrronium and Cannoterol were sifted with a part quantity of lactose.
W0 2012/1 10770 PCT/G32012/000171
2) The co-sift of step 1 was then sifted with the remaining quantity of e
blended.
3) The blend of step 2 was then filled in capsules.
Example 71
Sr. No. Ingredients Qty / unit (mg)
Process:
1) Giycopyrronium and Carmoterol were sifted with a
part quantity of lactose.
2) The co-sifi of step 1 was then sified with the ing quantity of lactose
blended.
3) The blend of step 2 was then filled in capsules.
Example 72
-Glycopyrronium 100 mcg
HFA134A OR HFA227
Process:
1) Glycopyrronium and Carmoterol were homogenized with
part quantity ofHFA.
2) The suspension obtained in Step 1 was transferred to the mixing vessel where
remaining ty ofHFA was added.
3) The resulting suspension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
PCT/G32012/000171
Example ‘73
Ingredients Qty ISpray
_Glycopyrronium 100 mcg
100% ofthe drug
4. HFA134A OR HFA227
Process:
1) erol and Glycopyrronium were nized with lactose and
part quantity of
HFA.
2) The suspension obtained in step 1 was erred to the mixing vessel where
remaining quantity ofHFA was added.
3) The resulting sion was mixed, recirculated and filled in into pre-crimped
aluminum cans.
Example 74
Sr. No. Ingredients Qty /Spray
Glycopyrronium 100 mcg
3. PEG400/1000 0.3% of total
formulation
4. PVP K 25 0.001% of total
formulation
HFA134A OR HFA227
q.s.
Process:
1) PVP was dissolved in PEG and part quantity of HFA134A or HFA227.
2) The solution obtained in Step 1 was transferred to a mixing vessel.
3) Cannoterol and Glycopyrronium were homogenized with a
part quantity of HFA.
4) The suspension obtained in step 3 was transferred to the mixing vessel where
remaining quantity of HFA was added.
) The resulting total suspension was mixed, ulated and filled in into
pre~crimped
aluminum cans.
Example 75
Ingredients Qty ISpray
-Glycopyrronium 100 mcg
3. Ethanol 15-20% of total
formulation
4. Glycerol 1% of total '
HCL ( 0.08N) pH 2.5 — 3.5
Process:
1) Glycerol was dissolved in ethanol and required quantity of HG]
was added.
2) Carmoterol and Glyeopyrronium were dissolved in the solution obtained in
step I.
3) The resulting solution was erred to the mixing vessel where HFA
was added.
4) The resulting suspension was mixed, recirculated and filled in into pre—erimped
aluminum cans.
Example 76
D 100 mcg
I- iOs»S5-?9... 2 mcg
3. l 15-20% of total
formulation
* .o533 pH 2.5-3.5
WO 10770
Process:
1) Required quantity of HCl was added to ethanol.
2) Carmoterol and Glycopyrronium were dissolved in the solution obtained in
step I.
3) The resulting solution was transferred to the mixing vessel where HFA was added.
4) The resulting suspension was mixed, recirculated and filled in into prevcrimped
aluminum cans.
Example 77
Sr. No. Ingredients Qty lSpray
1. Glycopyrronium 100 mcg
I. Ethanol 1-2% of total
formulation
0.02 of the API
. HFA134a or HFA227
Process:
1) Lecithin was dissolved in ethanol.
2) yrronium and Cannoterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) The solution obtained in step (1) was homogenized with part quantity ofHFA
4) The mixture obtained in step (3) was transferred to the main mixing vessel where the
remaining quantity ofHFA was added.
) The resulting suspensiorr was mixed, recirculated and filled in into precrimped
aluminum cans.
Example 78
Glycopyrronium 100 mcg
3. Ethanol 1-2% of total
formulation
4. Oleic acid 0.02 — 5% of the
Process:
]) Oleic acid was dissolved in ethanol.
2) Glycopyrronium and Carmoterol were homogenized with part quantity of HFA and
transferred to the mixing vessel.
3) The solution obtained in step (1) was homogenized with part quantity ofHFA
4) The mixture obtained in step (3) was transferred to the main mixing vessel where the
remaining ty of HFA was added.
) The resulting suSpension was mixed, recirculated and filled in into pre-crimped
aluminum cans.
It will be readily apparent to one skilled in the art that varying substitutions and
modifications may be made to the invention sed herein without departing from the
spirit of the invention. Thus, it should be understood that although the t invention
has been specifically disclosed by the preferred ments and optional features,
ation and variation of the concepts herein disclosed
may be resorted to by those
skilled in the art, and such modifications and variations are ered to be falling
within the scope of the invention.
It is to be understood that the phraseology and terminology used herein is for the
purpose
of description and should not be regarded as limiting. The use of “including,”
ising,” or “having” and variations thereof herein is meant to encompass the items
listed thereafter and equivalents thereof as well as additional items.
It must be noted that, as used in this specification and the
appended claims, the singular
forms "a," "an" and ”the" include plural references unless the context clearly dictates
otherwise. Thus, for example, reference to "an excipient" includes
a single ent as
well as two or more different excipients, and the like.
Claims (18)
1. A pharmaceutical composition comprising glycopyrrolate in combination with indacaterol and fluticasone, ally with one or more pharmaceutically acceptable excipients.
2. A pharmaceutical composition according to claim 1, wherein glycopyrrolate, indacaterol and/or fluticasone are in the form of a pharmaceutically acceptable salt, ester, solvate, e, enantiomer or polymorph.
3. A pharmaceutical composition according to claim 1 or 2, n indacaterol is present in an amount ranging from 25-800 mcg.
4. A pharmaceutical composition according to claim 1, 2 or 3, wherein the fluticasone is in the form of an ester.
5. A pharmaceutical composition according to any ing claim, wherein the fluticasone is present in an amount ranging from 25 ~800 mcg.
6. A pharmaceutical composition according to any preceding claim, wherein the fluticasone is in the form of fluticasone furoate.
7. A ceutical composition according to any preceding claim, wherein the glycopyrrolate is present in an amount ranging from 50-200 mcg.
8. A pharmaceutical composition according to any preceding claim, compiising glycopyrrolate, indacaterol maleate and fluticasone furoate.
9. A pharmaceutical composition according to any ing claim, in the form of te formulations or a single combined formulation.
10. A pharmaceutical composition ing to any preceding claim, formulated as a composition for inhalation.
11. A pharmaceutical composition according to claim 10, formulated as a composition for inhalation in the form of a metered dose inhaler (MDI), dry powder inhaler (DPI), zer, nasal spray, nasal drops or an insufflation powder.
12. A pharmaceutical composition according to any ing claim for once daily administration.
13. A process for manufacturing a pharmaceutical composition ing to any one of claims 1 to 12, sing combining glycopyrrolate with indacaterol and sone, optionally with one or more ceutically acceptable excipients.
14. Use of glycopyrrolate in combination with indacaterol and fluticasone, in the manufacture of a medicament for the prophylaxis or treatment of a respiratory, inflammatory or obstructive airway disease.
15. The use according to claim 14 wherein the disease is COPD or asthma.
16. A pharmaceutical composition according to claim 1, substantially as herein described with reference to the examples.
17. A process according to claim 13, substantially as herein described with reference to the examples.
18. The use according to claim 14, substantially as herein described with reference to any one of the Examples thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ707754A NZ707754B2 (en) | 2011-02-17 | 2012-02-17 | Combination of glycopyrrolate and a beta2 -agonist |
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN446/MUM/2011 | 2011-02-17 | ||
IN446MU2011 | 2011-02-17 | ||
IN694/MUM/2011 | 2011-03-11 | ||
IN694MU2011 | 2011-03-11 | ||
IN953MU2011 | 2011-03-28 | ||
IN953/MUM/2011 | 2011-03-28 | ||
IN1535MU2011 | 2011-05-19 | ||
IN1534/MUM/2011 | 2011-05-19 | ||
IN1534MU2011 | 2011-05-19 | ||
IN1535/MUM/2011 | 2011-05-19 | ||
IN1613/MUM/2011 | 2011-05-31 | ||
IN1613MU2011 | 2011-05-31 | ||
IN1965MU2011 | 2011-07-07 | ||
IN1965/MUM/2011 | 2011-07-07 | ||
IN1966MU2011 | 2011-07-07 | ||
IN1966/MUM/2011 | 2011-07-07 | ||
PCT/GB2012/000171 WO2012110770A2 (en) | 2011-02-17 | 2012-02-17 | Pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613915A NZ613915A (en) | 2015-08-28 |
NZ613915B2 true NZ613915B2 (en) | 2015-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11077124B2 (en) | Pharmaceutical compositions | |
US20170027908A1 (en) | Pharmaceutical Composition | |
US10179139B2 (en) | Pharmaceutical composition | |
WO2014016548A2 (en) | Pharmaceutical composition | |
WO2015193631A1 (en) | Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent | |
WO2012010854A1 (en) | Inhalation formulations comprising carmoterol in combination with a corticosteroid | |
US9402854B2 (en) | Pharmaceutical composition | |
WO2012093252A1 (en) | Pharmaceutical composition | |
NZ613915B2 (en) | Combination of glycopyrrolate, fluticasone and indacaterol | |
NZ707754B2 (en) | Combination of glycopyrrolate and a beta2 -agonist |